Abstract:Depression has severely impaired the health of the people all over the world. Cognitive dysfunction due to depression has exerted serious economic burden to family and society induced by the reduction of social functioning for patients. NDRIs targeted with norepinephrine transport (hNET) and distribution than dopamine transport (hDAT) simultaneously treat depression and improve cognitive function, and they effectively avoid sexual dysfunction and other side effects. However, the drugs of NDIRs are still performing poor response to many patients. So it is urgent to discover novel NDRIs antidepressants with the ability of improving the cognitive fuction. The aim of this work was to identify novel NDRIs candicates selectively against hNET and hDAT from large compound libraries by comprehensive strategy integrating SVM, ADME/T, molecular docking, vitro binding assays, molecular dynamics simulation and binding energy calculation. Firstly, 6,522 compounds without inhibiting serotonin transporter (hSERT) were hitted by SVM models of hNET, hDAT and non-target hSERT with similarities analysis from compound libraries. ADME/T and molecular docking were then used to filter compounds which could potently bind in hNET and hDAT with good ADME/T, and 4 compounds were successfully identified. According to their docking scors and ADME/T information, 3719810 was advanced for profiling in vitro assays as novel NDRIs lead compound attributing to its best druggability and balance activities. Encouragingly, 3719810 performed comparative activities on two targets with Ki value 7.32 μM for hNET and 5.23μM for hDAT. In order to abtain candicates with more activities and balance activities of 2 targets, 5 analogs were optimized and 2 novel scaffold compounds were successively designed. By assessment of molecular docking, molecular dynamics simulation and binding energy calculation, 5 compounds were validated as NDRIs candicates with high activties, and 4 out of them performed acceptable balance actives acting on hNET and hDAT, which could supply promising novel NDRIs to exploit drugs for depression with cognitive dysfunction or other related neruodegenrative disorders, and also shed sight on screening inhibitors for dual-target with homological non-target on highly efficient and cost-effective.

What Contributes to SNRIs' Dual-targeting Mechanism? The Key Role of TM6 Domain in hSERT and hNET Revealed by Molecular Dynamics Simulation.

Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study.

Understanding The Polypharmacological Profiles Of Triple Reuptake Inhibitors By Molecular Simulation

Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study

Computational Characterization of the Selective Inhibition of Human Norepinephrine and Serotonin Transporters by an Escitalopram Scaffold

Exploring Unbinding Mechanism of Drugs from SERT Via Molecular Dynamics Simulation and Its Implication in Antidepressants

Differentiating Physicochemical Properties Between NDRIs and Snris Clinically Important for the Treatment of ADHD.

Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket

Comparison of computational model and X-ray crystal structure of human serotonin transporter: potential application for the pharmacology of human monoamine transporters

Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder.

The mechanism of a high-affinity allosteric inhibitor of the serotonin transporter

A Multiple-step Screening Protocol to Identify Norepinephrine and Dopamine Reuptake Inhibitors for Depression

Molecular Mechanism for the Allosteric Inhibition of the Human Serotonin Transporter by Antidepressant Escitalopram

Revealing Vilazodone's Binding Mechanism Underlying Its Partial Agonism to the 5-HT1A Receptor in the Treatment of Major Depressive Disorder

Identification of Dual Active Agents Targeting 5-HT1A and SERT by Combinatorial Virtual Screening Methods

Recent Developments in the Design of Anti-Depressive Therapies: Targeting the Serotonin Transporter

Serotonin 2A Receptor Polymorphism Rs3803189 Mediated by Dynamics of Default Mode Network: a Potential Biomarker for Antidepressant Early Response.

5-HTR2B and SLC6A3 as potential molecular targets of sertraline in the treatment of major depressive disorder: the use of bioinformatics and its practical implication

The binding mode of vilazodone in the human serotonin transporter elucidated by ligand docking and molecular dynamics simulations.

Uncovering the Elusive Structures and Mechanisms of Prevalent Antidepressants

Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants